8-K: Telomir Pharmaceuticals Reports Positive Preclinical Data for Oral AMD Treatment Telomir-1, Demonstrating Vision Restoration and Survival Benefit

Telomir Pharmaceuticals, Inc. announced significant preclinical data for its investigational oral small molecule Telomir-1, showing restoration of vision and retinal structure in an age-related macular degeneration (AMD) animal model.

Summary

• Telomir Pharmaceuticals, Inc. released new preclinical data for Telomir-1, an oral small molecule candidate for age-related macular degeneration (AMD).
• The study was conducted on an 18-month-old Sen57wrn-/-ND6-/+ zebrafish model, which mimics key features of dry AMD and geographic atrophy.
• Animals treated orally with Telomir-1 for 14 days showed improved central vision response and motion detection, with significantly enhanced reaction to visual stimuli.
• Histological analysis revealed regeneration of critical retinal layers, including the inner nuclear layer (INL), ganglion cell layer (GCL), inner plexiform layer (IPL), and outer plexiform layer (OPL), with measurable increases in thickness.
• Reactive oxygen species (ROS) levels, which were elevated approximately fourfold in untreated diseased animals, were reduced by up to 50% following Telomir-1 treatment.
• No mortality was observed in any Telomir-1 treated group during the two-week study period, compared to a 15% mortality rate in untreated animals.
• The company believes these results represent a significant preclinical milestone, supporting the advancement of Telomir-1 toward Investigational New Drug (IND) submission.
• The study utilized endpoints consistent with FDA-recognized surrogate markers for visual function.

Sentiment

Score: 9

Explanation: The document reports highly positive preclinical results for a key drug candidate, demonstrating significant efficacy across multiple critical endpoints (vision, retinal structure, oxidative stress, survival) in a validated animal model, and aligns with FDA-recognized endpoints, indicating strong progress towards clinical development.

Positives

• Telomir-1 demonstrated functional vision improvement in treated animals, including enhanced central vision response and motion detection.
• The treatment led to significant retinal structural restoration, with regeneration and increased thickness of key retinal layers (INL, GCL, IPL, OPL).
• Oxidative stress, a key factor in AMD, was significantly reduced by up to 50% in treated animals.
• Telomir-1 treatment resulted in a 0% mortality rate, compared to a 15% mortality rate in untreated diseased animals.
• The study utilized FDA-recognized surrogate endpoints, which supports the drug's continued advancement towards IND submission.
• Telomir-1 is an oral small molecule, which could offer a more convenient administration route compared to current AMD treatments.

Future Outlook

Telomir Pharmaceuticals intends to continue advancing Telomir-1 towards Investigational New Drug (IND) submission, leveraging the positive preclinical data and the use of FDA-recognized surrogate markers for visual function.

Management Comments

• Erez Aminov, Chief Executive Officer, stated that the results represent a significant preclinical milestone, demonstrating Telomir-1's ability to restore vision-related function, regenerate damaged retinal tissue, reduce oxidative stress, and improve survival in a validated AMD model.

Industry Context

Age-related macular degeneration (AMD) is a leading cause of vision loss globally, with limited treatment options, particularly for dry AMD and geographic atrophy. The preclinical success of an oral small molecule like Telomir-1, demonstrating both functional and structural improvements, could represent a significant advancement in the field, potentially offering a more accessible and less invasive treatment alternative compared to existing injectable therapies for wet AMD.

Comparison to Industry Standards

• The use of the Sen57wrn-/-ND6-/+ zebrafish model, which incorporates genetic mutations associated with premature aging, mitochondrial dysfunction, and chronic senescence, is a validated preclinical model mimicking key features of human dry AMD and geographic atrophy.
• The study's utilization of FDA-recognized surrogate endpoints for visual function, such as central vision response and motion detection, aligns with regulatory expectations for early-stage drug development, providing a strong foundation for future clinical trials.
• While direct comparisons to human clinical trial results of approved AMD drugs (e.g., anti-VEGF therapies for wet AMD like Lucentis or Eylea) are not applicable at this preclinical stage, the demonstration of retinal regeneration and oxidative stress reduction in an animal model for dry AMD is a promising indicator, as current treatments for dry AMD are limited.

Stakeholder Impact

• **Shareholders**: Positive preclinical data could lead to increased investor confidence and potential share price appreciation due to the promising development of a key pipeline asset.
• **Patients**: The successful development of Telomir-1 could offer a novel, orally administered treatment option for age-related macular degeneration, particularly dry AMD, which currently has limited therapies.
• **Employees**: Positive drug development milestones can boost morale and provide job security within the company.
• **Regulatory Authorities**: The use of FDA-recognized surrogate endpoints in preclinical studies facilitates the regulatory review process and supports future IND submission.

Next Steps

• Continued advancement of Telomir-1 toward Investigational New Drug (IND) submission.

Key Dates

Keywords

Telomir Pharmaceuticals, Telomir-1, Age-related macular degeneration, AMD, Preclinical data, Vision restoration, Retinal regeneration, Oxidative stress, Zebrafish model, Investigational New Drug, IND submission, Oral small molecule, Biotechnology, Pharmaceuticals, Ophthalmology